Merck’s HIV Combo Shows Non-Inferiority To Gilead’s Biktarvy

The company is developing doravirine and islatravir together as an alternative to therapies containing integrase inhibitors, like Biktarvy, especially as HIV patients age.

• Source: Shutterstock

More from Anti-infective

More from Scrip